文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

DNA C 环是端粒的替代延长活动的特异性和可量化的标志物。

DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity.

机构信息

Children's Medical Research Institute, University of Sydney, New South Wales, Australia.

出版信息

Nat Biotechnol. 2009 Dec;27(12):1181-5. doi: 10.1038/nbt.1587.


DOI:10.1038/nbt.1587
PMID:19935656
Abstract

Alternative lengthening of telomeres (ALT) is likely to be an important target for anticancer treatment as approximately 10% of cancers depend on this telomere maintenance mechanism for continued growth, and inhibition of ALT can cause cellular senescence. However, no ALT inhibitors have been developed for therapeutic use because of the lack of a suitable ALT activity assay and of known ALT-specific target molecules. Here we show that partially single-stranded telomeric (CCCTAA)(n) DNA circles (C-circles) are ALT specific. We provide an assay that is rapidly and linearly responsive to ALT activity and that is suitable for screening for ALT inhibitors. We detect C-circles in blood from ALT(+) osteosarcoma patients, suggesting that the C-circle assay (CC assay) may have clinical utility for diagnosis and management of ALT(+) tumors.

摘要

端粒的替代性延长(ALT)可能是癌症治疗的一个重要靶点,因为大约 10%的癌症依赖这种端粒维持机制来持续生长,而抑制 ALT 会导致细胞衰老。然而,由于缺乏合适的 ALT 活性测定方法和已知的 ALT 特异性靶分子,尚未开发出用于治疗用途的 ALT 抑制剂。在这里,我们证明部分单链端粒(CCCTAA)(n)DNA 环(C 环)是 ALT 特异性的。我们提供了一种快速且线性响应 ALT 活性的测定方法,适用于筛选 ALT 抑制剂。我们在 ALT(+)骨肉瘤患者的血液中检测到 C 环,这表明 C 环测定(CC 测定)可能具有用于 ALT(+)肿瘤的诊断和管理的临床应用价值。

相似文献

[1]
DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity.

Nat Biotechnol. 2009-12

[2]
The C-Circle Assay for alternative-lengthening-of-telomeres activity.

Methods. 2017-2-1

[3]
G-quadruplex Stabilization Fuels the ALT Pathway in ALT-positive Osteosarcoma Cells.

Genes (Basel). 2020-3-13

[4]
DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta.

Mol Hum Reprod. 2016-11

[5]
Xrcc3 and Nbs1 are required for the production of extrachromosomal telomeric circles in human alternative lengthening of telomere cells.

Cancer Res. 2007-2-15

[6]
The C-Circle Biomarker Is Secreted by Alternative-Lengthening-of-Telomeres Positive Cancer Cells inside Exosomes and Provides a Blood-Based Diagnostic for ALT Activity.

Cancers (Basel). 2021-10-26

[7]
Prevalence of alternative lengthening of telomeres in pediatric sarcomas determined by the telomeric DNA C-circle assay.

Front Oncol. 2024-8-19

[8]
Telomerase suppresses formation of ALT-associated single-stranded telomeric C-circles.

Mol Cancer Res. 2013-3-15

[9]
Telomeric C-circles localize at nuclear pore complexes in Saccharomyces cerevisiae.

EMBO J. 2022-3-15

[10]
Detection of alternative lengthening of telomeres by telomere quantitative PCR.

Nucleic Acids Res. 2012-8-25

引用本文的文献

[1]
PUMA-induced apoptosis drives bone marrow failure and genomic instability in telomerase-deficient mice.

Cell Death Differ. 2025-8-19

[2]
Distinct mechanisms underlying extrachromosomal telomere DNA generation in ALT cancers.

Nucleic Acids Res. 2025-8-11

[3]
Cellular adaptations impact the biological activity of naphthalene diimide G-quadruplex ligands in ALT-positive osteosarcoma cells.

Cell Death Dis. 2025-8-1

[4]
Conserved and unique features of terminal telomeric sequences in ALT-positive cancer cells.

Elife. 2025-8-1

[5]
Telomere interactions and structural variants in ALT cells revealed with TelSPRITE.

bioRxiv. 2024-11-22

[6]
Non-canonical functions of DNMT3A in hematopoietic stem cells regulate telomerase activity and genome integrity.

Cell Stem Cell. 2025-7-10

[7]
TRF1 relies on fork reversal to prevent fragility at human telomeres.

Nat Commun. 2025-7-11

[8]
Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma.

NPJ Precis Oncol. 2025-7-7

[9]
Extrachromosomal circular DNA drives dynamic genome plasticity: emerging roles in disease progression and clinical potential.

Theranostics. 2025-5-25

[10]
Targeting FANCM using the antisense oligonucleotides to treat the ALT-positive cancers.

Mol Ther Nucleic Acids. 2025-5-23

本文引用的文献

[1]
Control of telomere length by a trimming mechanism that involves generation of t-circles.

EMBO J. 2009-4-8

[2]
Unusual telomeric DNAs in human telomerase-negative immortalized cells.

Mol Cell Biol. 2009-2

[3]
Quantitative telomeric overhang determination using a double-strand specific nuclease.

Nucleic Acids Res. 2008-2

[4]
Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres.

Nucleic Acids Res. 2007

[5]
Ku suppresses formation of telomeric circles and alternative telomere lengthening in Arabidopsis.

Mol Cell. 2007-7-6

[6]
The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins.

Nat Struct Mol Biol. 2007-7

[7]
Circulating nucleic acids in plasma/serum.

Pathology. 2007-4

[8]
A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT.

Oncogene. 2005-11-24

[9]
Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies.

Cancer Res. 2005-4-1

[10]
Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex.

Mol Cell Biol. 2005-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索